Abstract
Lichen Sclerosus is a chronic inflammatory skin disease predominantly affecting post-menopausal women. Currently, the first line treatment approach for lichen sclerosus is ultra potent topical corticosteroids for 12 weeks. A treatment challenge to this approach is the risk of steroid atrophy due to the use of potent topical steroids on the genital skin. We describe reduction of erythema and symptomatic improvement following treatment with topical roflumilast 0.3% once daily in a patient with lichen sclerosus who refused topical corticosteroids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
